‘Hy's law,’ the ‘Rezulin Rule,’ and other predictors of severe drug‐induced hepatotoxicity: putting risk‐benefit into perspective

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2006-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pds.1209PMID 16444771
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Valproate‐Induced Hepatic Injury: Analyses of 23 Fatal Cases

  2007cited by this paper
• A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience

  2006cited by this paper
• Hepatic Findings in Long-Term Clinical Trials of Ximelagatran

  2005cited by this paper
• Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program

  2005cited by this paper
• Insight into hepatotoxicity: The troglitazone experience

  2005cited by this paper
• Human and animal hepatocytes in vitro with extrapolation in vivo.

  2004cited by this paper
• Drug‐induced liver injury network (DILIN)

  2004cited by this paper
• Expecting the unexpected--drug safety, pharmacovigilance, and the prepared mind.

  2004cited by this paper
• Acetaminophen and the U.S. acute liver failure study group: Lowering the risks of hepatic failure

  2004cited by this paper
• Hormone therapy: making decisions in the face of uncertainty.

  2004cited by this paper
• Is that it, then, for blockbuster drugs?

  2004cited by this paper
• Liver transplantation for acute liver failure from drug induced liver injury in the United States

  2004cited by this paper
• Drug- and chemical-induced cholestasis.

  2004cited by this paper
• Postoperative jaundice.

  2004cited by this paper
• Screening in liver disease: Report of an AASLD clinical workshop

  2004cited by this paper
• Incidence and preventability of adverse drug events among older persons in the ambulatory setting.

  2003cited by this paper
• Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.

  2003cited by this paper
• Medication safety: moving from illusion to reality.

  2003cited by this paper
• Pharmacogenomics--drug disposition, drug targets, and side effects.

  2003cited by this paper
• Drug-induced hepatotoxicity.

  2003cited by this paper
• Incidence of Idiopathic Acute Liver Failure and Hospitalized Liver Injury in Patients Treated With Troglitazone

  2003cited by this paper
• Inheritance and drug response.

  2003cited by this paper
• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

  2003cited by this paper
• Differences between clinical trials and postmarketing use.

  2003cited by this paper
• Troglitazone-induced liver failure: a case study.

  2003cited by this paper
• Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease.

  2003cited by this paper
• A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents.

  2003cited by this paper
• Differentiating members of the thiazolidinedione class: a focus on safety

  2002cited by this paper
• Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project

  2002cited by this paper
• Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States

  2002cited by this paper
• Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

  2002cited by this paper
• Diabetes increases the risk of acute hepatic failure.

  2002cited by this paper
• The rational use of potentially hepatotoxic medications in patients with underlying liver disease

  2002cited by this paper
• Improving adverse-drug-reaction reporting in ambulatory care clinics at a Veterans Affairs hospital.

  2002cited by this paper
• Management of drug-induced liver disease

  2001cited by this paper
• Potential risks and prevention, Part 3: Drug-induced threats to life.

  2001cited by this paper
• Drug‐induced liver injury: Mechanisms and test systems

  2001cited by this paper
• Liver enzyme monitoring in patients treated with troglitazone.

  2001cited by this paper
• Factors Associated with the Risk of Liver Enzyme Elevation in Patients with Type 2 Diabetes Treated with a Thiazolidinedione

  2001cited by this paper
• Troglitazone (Rezulin) and hepatic injury

  2001cited by this paper
• Serious liver injury. Leading reason for drug removals, restrictions.

  2001cited by this paper
• Chronic Dizziness in Older Adults

  2000cited by this paper
• Assessing causality in drug-induced liver injury.

  2000cited by this paper
• Rosiglitazone and Hepatic Failure

  2000cited by this paper
• Accuracy of hepatic adverse drug reaction reporting in one English health region

  1999cited by this paper
• Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group.

  1999cited by this paper
• Bromfenac(Duract)-associated hepatic failure requiring liver transplantation

  1999cited by this paper
• Drug- and chemical-induced cholestasis.

  1999cited by this paper
• Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation

  1999cited by this paper
• Tacrine. A cause of fatal hepatotoxicity?

  1998cited by this paper
• Hepatic dysfunction associated with troglitazone.

  1998cited by this paper
• Safety of Tacrine: Clinical Trials, Treatment IND, and Postmarketing Experience

  1998cited by this paper
• Development and validation of a clinical scale for the diagnosis of drug‐induced hepatitis

  1997cited by this paper
• Hepatotoxicity in drug development: detection, significance and solutions.

  1997cited by this paper
• Diclofenac‐associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactions

  1995cited by this paper
• Drug-induced hepatotoxicity.

  1995cited by this paper
• Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.

  1994cited by this paper
• Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration.

  1993cited by this paper
• Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.

  1993cited by this paper
• Labetalol hepatotoxicity.

  1990cited by this paper
• Criteria of drug-induced liver disorders. Report of an international consensus meeting.

  1990cited by this paper
• Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting.

  1990cited by this paper
• Pemoline-associated hepatic injury.

  1990cited by this paper
• Drug-induced liver disease.

  1989cited by this paper
• Labetalol hepatotoxicity.

  1989cited by this paper
• Postoperative Jaundice

  1988cited by this paper
• Is enflurane hepatotoxic?

  1986cited by this paper
• The morphologic spectrum of halothane‐induced hepatic injury: Analysis of 77 cases

  1985cited by this paper
• Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.

  1985cited by this paper
• Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases.

  1984cited by this paper
• Ticrynafen‐Associated Hepatic Injury: Analysis of 340 Cases

  1984cited by this paper
• Drug induced liver disease.

  1983cited by this paper
• Enflurane hepatotoxicity. A clinicopathologic study of 24 cases.

  1983cited by this paper
• Effects of aspirin and acetaminophen on the liver.

  1981cited by this paper
• Phenylbutazone liver injury: A clinical‐pathologic survey of 23 cases and review of the literature

  1981cited by this paper
• Chronic Active Hepatitis and Severe Hepatic Necrosis Associated with Nitrofurantoin

  1980cited by this paper
• Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver

  1978cited by this paper
• Dantrolene-associated hepatic injury. Incidence and character.

  1977cited by this paper
• Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.

  1976cited by this paper
• Isoniazid-associated hepatitis in 114 patients.

  1975cited by this paper
• Diphenylhydantoin sodium hepatitis.

  1968cited by this paper
• SOME PRELIMINARY CLINICAL AND BIOCHEMICAL ASPECTS OF LIVER FUNCTION IN PATIENTS RECEIVING IPRONIAZID

  1959cited by this paper

• Incidence, predictors, bacterial isolate, antibiotic susceptibility pattern and treatment outcomes among patients who underwent major surgery in public hospitals in Eastern Ethiopia: a prospective multicenter cohort study

  2025influential citation
• Modifying Hy’s Law and eDISH for the modern idiosyncratic DILI era

  2025cites this paper
• Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database

  2024cites this paper
• Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system

  2024cites this paper
• Genome-wide association study of abnormal elevation of ALT in patients exposed to atabecestat

  2023cites this paper
• Tandem mass tag­based quantitative proteomic profiling identifies novel serum biomarkers of drug­induced liver injury in humans

  2023cites this paper
• Systematic Review and Meta-Analysis: Comparing Hepatocellular and Cholestatic Patterns of Drug Induced Liver Injury

  2023cites this paper
• Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans

  2023cites this paper
• Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate.

  2022cites this paper
• Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology

  2022cites this paper
• The Origins of the Modern‐Day Study of Drug Hepatotoxicity: Focus on Hyman J. Zimmerman

  2020cites this paper
• Drug-Induced Liver Injury (DILI) in Patients with Depression Treated with Antidepressants: A Retrospective Multicenter Study

  2020cites this paper
• Hepatotoxicity: Mechanisms of Liver Injury

  2020cites this paper
• In silico prediction of drug-induced liver injury: Quo vadis?

  2019cites this paper
• Early Phase Metabolic Research with Reference to Special Populations

  2019cites this paper
• Methodologies of Safety Assessment in Clinical Pharmacology

  2018cites this paper
• An Introduction to DILIsym ® Software, a Mechanistic Mathematical Representation of Drug-Induced Liver Injury

  2018cites this paper
• Drugs and Toxins

  2018cites this paper
• Oštećenje jetre ksenobioticima

  2018cites this paper
• Hy’s Law and eDISH for Clinical Studies

  2018cites this paper
• Individual serum bile acid profiling in rats aids in human risk assessment of drug‐induced liver injury due to BSEP inhibition

  2018cites this paper
• Exploration of potential biomarkers for amoxicillin/clavulanate-induced liver injury in humans through multi-omics approaches

  2017influential citation
• Drug-induced liver injury in Oncology

  2017cites this paper
• Drug-induced liver injury: recent advances in diagnosis and risk assessment

  2017cites this paper
• Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review

  2016cites this paper
• Clinical hepatotoxicity associated with antifungal agents

  2016cites this paper
• Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies

  2016cites this paper
• Chinese experts' consensus on diagnosis, prevention, and treatment of chemotherapy-induced hepatotoxicity

  2015cites this paper
• The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond.

  2015cites this paper
• Enoxaparin-Induced Liver Injury: Case Report and Review of the Literature and FDA Adverse Event Reporting System (FAERS)

  2015cites this paper
• Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system

  2015cites this paper
• Drug-Induced Liver Injury and Individual Cell Models

  2015cites this paper
• Cellular and Molecular Aspects of Drug-Induced Liver Toxicity: Recent Prominent Mechanisms

  2015cites this paper
• Gauging reactive metabolites in drug-induced toxicity.

  2014cites this paper
• Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cites this paper
• [Unexplained, subclinical chronically elevated transaminases].

  2013cites this paper
• New Insights into Toxicity and Drug Testing

  2013cites this paper
• Pre-Clinical Assessment of the Potential Intrinsic Hepatotoxicity of Candidate Drugs

  2013cites this paper
• Drug-Induced Liver Injury: Introduction and Overview

  2013cites this paper
• Élévation modérée, persistante et inexpliquée des transaminases

  2013cites this paper
• Nonsteroidal antiinflammatory drugs and leukotriene receptor antagonists

  2013cites this paper
• Incidence of potential drug interactions in medication prescriptions for children and adolescents in the University Hospital Olomouc, Czech Republic

  2013cites this paper
• Clinical manifestations and management of drug-induced liver diseases

  2013cites this paper
• Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical Hepatologist

  2013cites this paper
• Why the threshold criteria should not be modified for detection of possibly serious drug‐induced hepatotoxicity in special groups of trial subjects

  2013cites this paper
• 13 – Hepatic injury due to drugs, herbal compounds, chemicals and toxins

  2012cites this paper
• Truncated Robust Distance for Clinical Laboratory Safety Data Monitoring and Assessment

  2012cites this paper
• The adaptive response (drug tolerance) helps to prevent drug-induced liver injury.

  2012cites this paper
• The propylthiouracil dilemma

  2012cites this paper
• Managing IADRs – a Risk–Benefit Analysis

  2012cites this paper
• Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

  2012cites this paper
• Drug-induced liver injury: a summary of recent advances

  2011cites this paper
• Adverse Effects of Drugs and Toxins on the Liver

  2011cites this paper
• Idiosyncratic Drug-Induced Liver Injury: A Clinical Update

  2011cites this paper
• Translational Biomarkers of Acute Drug‐Induced Liver Injury: The Current State, Gaps, and Future Opportunities

  2010cites this paper
• C.4 Methodologies of Safety Assessment in Clinical Pharmacology

  2010cites this paper
• Gone (from the Physicians' desk reference) but not forgotten: propylthiouracil-associated hepatic failure: a call for liver test monitoring.

  2010cites this paper
• Deferasirox induced liver injury in haemochromatosis.

  2010cites this paper
• Predicting and preventing acute drug-induced liver injury: what's new in 2010?

  2010cites this paper
• A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group.

  2010cites this paper
• Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury.

  2010influential citation
• Recommendations to qualify biomarker candidates of drug-induced liver injury.

  2010cites this paper
• Chapter 25 – Drug-Induced Liver Disease

  2010cites this paper
• Pharmacogenetics of drug‐induced liver injury

  2010cites this paper
• Drug-induced liver injury: what was new in 2008?

  2009cites this paper
• How Common Is Diclofenac-Associated Liver Injury? Analysis of 17,289 Arthritis Patients in a Long-Term Prospective Clinical Trial

  2009cites this paper
• Monitoring for Hepatotoxicity: What Is the Predictive Value of Liver “Function” Tests?

  2009cites this paper
• Drug-induced hepatotoxicity in humans.

  2008cites this paper
• Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events.

  2008cites this paper
• Hepatic effects of duloxetine-I: non-clinical and clinical trial data.

  2008cites this paper
• Preventive Approaches in Chronic Liver Diseases, Part I

  2008cites this paper
• Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population

  2008cites this paper
• Chapter 30 – Liver Disease in Renal Transplant Recipients

  2008cites this paper
• Questioning the Role of Routine Liver Enzyme Monitoring in Statin Therapy

  2008cites this paper
• Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran.

  2008cites this paper
• Acute Liver Failure Due to Drugs

  2008cites this paper
• Hepatic Bioactivation and Drug-Induced Liver Injury

  2008cites this paper
• Clinical Pattern of Zileuton-Associated Liver Injury

  2007cites this paper
• Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial

  2007cites this paper
• Drug-Induced Liver Injury

  2007cites this paper
• Monitoring liver safety in drug development: the GSK experience.

  2007cites this paper
• Drug-induced liver disease in 2006

  2007cites this paper
• Public Health Aspects of Pharmaceutical Prescription Patterns Exemplified by treatments for prevention of cardiovascular disease

  2007cites this paper
• Rules and laws of drug hepatotoxicity

  2006cites this paper
• How can ‘Hy's law’ help the clinician?

  2006cites this paper